Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

January 9th 2015

Nanotechnology, Hailed in Biomedicine, Could Have Cardiac Effects, Study Finds

While nanotechnology has led to countless advancements, a group of Israeli researchers are now raising a flag of caution about its effects on our health. They say exposure to tiny silica-based particles can play a big role in increasing heart attack and stroke risks.

January 9th 2015

Controlling Cancer Metastases To Prevent Disease Progression

Research at Heildelberg University is targeting the production of tumor-promoting growth factors in endothelial cells to prevent metastasis. Pre-clinical results using this strategy in a mouse model reduced lung and bone metastases in treated mice and also improved survival over the control chemotherapy-treated animals.

January 8th 2015

NCCN and Flatiron to Collaborate for Improved Patient-Centered Care

A new collaboration between NCCN and Flatiron Health will provide the opportunity to analyze key quality and outcomes metrics and identify trends and patterns in the care of patients with cancer.

January 8th 2015

The Debate on HPV Screening in Cervical Cancer

Following FDA approval of a DNA test to detect the HPV virus last year, the medical community is split over which test is more appropriate as a primary screen for cervical cancer in women.

January 8th 2015

Leading Cancer Research Groups Call for US Regulation of E-Cigarettes

Mary K. Caffrey

ASCO and AACR called on the FDA to regulate e-cigarettes and other electronic nicotine delivery systems and for more research to occur to find out how long-term use affects health. Leaders of these groups said that e-cigarettes could cause nicotine addiction among teens, and CDC data show rising use of the products among middle- and high-schoolers.

January 8th 2015

A Relatively Safe Breast Cancer Combination Therapy Proves Effective

The study published in the New England Journal of Medicine found nearly 100% survival with adjuvant paclitaxel and trastuzumab.

January 7th 2015

ODAC Recommends First Biosimliar for Approval to the FDA

The investigational drug by Sandoz, filgrastim, a biological similar to Amgen's Neupogen, is already approved for use in more than 40 countries worldwide.

January 7th 2015

Night Shift Work Is Not Heart Healthy, Study Finds

A new study has identified an increased risk of lung cancer and heart disease in night shift workers, adding to the growing knowledge of health risks associated with those jobs.

January 7th 2015

Cancer: A Genetic Gamble

A paper published in Science Magazine this month, co-authored by a mathematician and a biologist, suggests that heredity and environmental factors account for only one-third of the risk for developing cancer. A majority of risk is associated with random mutations, a result of mistakes during normal cellular replication.

January 6th 2015

Cancer Patients Not Too Distressed by Advanced Directives

A study conducted at the humanities and medicine departments at Penn State College of Medicine in Hershey, Pennsylvania, found that there's never an ideal time to talk to cancer patients about end-of-life decisions, and most patients are not too disturbed by these discussions.

January 6th 2015

Nanotechnology for Surgical Success and Phototherapy in Cancer

Scientists at Oregon State University have developed fluorescent nanoparticles that can aid in the removal of malignant tumors and also kill any remaining malignant cancer cells.

January 5th 2015

Will Neupogen Prove the Poster Child for Increased Access to Cheaper Biosimilars?

If the biological developed by Novartis to imitate Amgen's Neupogen is approved by the FDA, it'd open floodgates as other biosimilars find their way to the FDA's doorsteps. The cheaper alternatives would prove a tremendous cost-saving to the healthcare industry.

January 3rd 2015

ACA Can Help Smokers Quit, Experts Write

A perspective published in the New England Journal of Medicine affirms that provisions of the Affordable Care Act will allow improved coverage of smoking cessation tools, which could be a big boost in the number of smokers planning to quit.

January 3rd 2015

More Than 1.5 Million Cancer Deaths Averted in Last 2 Decades

Rates of cancer deaths have declined 22% over the last 2 decades, which amounts to 1.5 million deaths averted, according to the annual cancer statistics report from the American Cancer Society.

January 3rd 2015

NICE Uses Comparitive Effectiveness for Nab-Paclitaxel in Pancreatic Cancer

NICE has published draft guidance which recommends that nab-paclitaxel given with gemcitabine should not be funded by the NHS for previously untreated metastatic pancreatic cancer, because its limited benefits compared to current treatments do not justify its cost.

January 1st 2015

A New Hope in Advanced Lung Cancer

Combining erlotinib with SBRT more than doubled the survival time of stage 4 lung cancer patients.

December 30th 2014

The Year in Review: Most-Read Stories of 2014

Laura Joszt, MA

With 2014 coming to a close, The American Journal of Managed Care is taking a look back at the most popular articles from this year. These most-read articles highlight the healthcare issues most important to providers, insurers, and policy makers.

December 28th 2014

Blackberry Competes With Apple for Healthcare Apps

Blackberry announced the product of their collaboration with NantHealth: a healthcare app for doctors and nurses who use their smartphones.

December 27th 2014

Gardasil 9 Approved for 5 Additional HPV Types

With this approval, the vaccine can effectively protect against 5 additional types of HPV than the parent Gardasil vaccine, thereby preventing the development of cervical, vulvar and vaginal cancers, based on a randomized clinical trial.

December 27th 2014

Immuno-Oncology Getting Closer to Being Personalized: Nature Study

The Nature letter published results showing that the monoclonal antibody targeting PD-1 had antitumor activity, but more importantly, the response was greater in patients overexpressing the PD-L1 receptor, thereby opening the doors for targeted therapy.

December 21st 2014

ASCO Releases Guidelines to Improve Patient Awareness and Participation in Phase I Trials

The American Society of Clinical Oncology called for greater access to and education about phase I clinical trials, the first-in-human studies of new agents designed to fight cancer.

December 21st 2014

Lanreotide Approved for Gastroenteropancreatic Neuroendocrine Tumors

The approval was based on the results of a clinical trial that demonstrated improved PFS in patients on lanreotide. While the median PFS in the placebo arm was 16 months, patients in the lanreotide arm had not yet reached median PFS at the time of analysis, and it was anticipated to extend beyond 22 months.

December 20th 2014

Bayer's Xofigo Gains NICE Approval

The National Institute for Health and Care Excellence has issued draft guidelines on using the drug in prostate cancer patients.

December 17th 2014

Treatment Decisions and Unmet Needs

December 17th 2014

Anti-Androgens and Combination Regimens in CRPC

December 17th 2014

Early Indication of Androgen Deprivation Resistance

December 17th 2014

Diagnostic and Prognostic Biomarkers

December 17th 2014

Episode 3 - The CHAARTED Study-Treatment of CRPC with Docetaxel

December 17th 2014

Episode 2 - Variability in Disease Course and Treatment Approach

December 17th 2014

Episode 1 - Defining and Detecting CRPC

...

145 146 147 148 149 150 151 152 153

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions